Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s).

"Disclosures Barry S. Coller is an inventor of abciximab and zalunfiban. In accordance with US federal law and the policies of the Research Foundation of the State of New York, he receives royalties on the sale of abciximab. He is a founder and equity holder in CeleCor Therapeutics, which is developing zalunfiban, and a paid consultant to CeleCor. Rockefeller University licensed zalunfiban to CeleCor and in accordance with US federal law and the policies of Rockefeller University, Dr Coller will share in sales of zalunfiban if it is approved for human use. Arnoud W. J. van 't Hof reports unrestricted grants from AstraZeneca, Medtronic, Boehringer Ingelheim, Abbott Vascular, and Ferrer. He serves as a scientific advisor to CeleCor. Jurrien M. ten Berg reports grants from the Netherlands Organization for Health Research and Development, a Dutch government institution called ZonMw. He reports speaker fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer‐Ingelheim, Bayer, BMS, Pfizer, and Ferrer. He serves as a scientific advisor to CeleCor. Dean J. Kereiakes is a consultant to CeleCor. Sem A.O.F. Rikken has no disclosures to report."

"Sources of Funding This work was supported in part by grant 19278 from the National Heart, Lung and Blood Institute, and grant UL1 TR001866 from the National Center for Advancing Translational Sciences of the US National Institutes of Health."